Short answer: Medicare Part D now covers weight loss drugs for obesity starting in 2026, thanks to changes from the Inflation Reduction Act. However, coverage varies by plan, and not every GLP-1 medication is covered the same way. Here's exactly what you need to know.
What Are GLP-1 Weight Loss Drugs?
GLP-1 receptor agonists are a class of injectable medications originally developed for type 2 diabetes. They work by mimicking a natural hormone that regulates appetite and blood sugar. The most well-known include:
- Ozempic (semaglutide) - FDA-approved for type 2 diabetes; widely used off-label for weight loss
- Wegovy (semaglutide) - FDA-approved specifically for chronic weight management
- Mounjaro (tirzepatide) - approved for type 2 diabetes; also used for weight loss
- Zepbound (tirzepatide) - approved for chronic weight management
These drugs have shown remarkable results - average weight loss of 15-20% of body weight in clinical trials - which is why demand has skyrocketed.
Did Medicare Always Cover Weight Loss Drugs?
No. Until 2025, Medicare Part D was explicitly prohibited from covering drugs prescribed solely for weight loss or cosmetic purposes. This was a decades-old exclusion written into the Medicare Modernization Act of 2003.
However, Medicare did cover GLP-1 drugs when prescribed for their FDA-approved diabetes indication. So if you had type 2 diabetes, Ozempic and Mounjaro were covered. If you had obesity without diabetes, you were out of luck - even if your doctor recommended the same medication.
What Changed in 2026?
The Treat and Reduce Obesity Act, signed into law as part of broader Medicare reforms, removed the anti-obesity medication exclusion from Part D. Starting January 1, 2026:
- Medicare Part D plans can now cover FDA-approved anti-obesity medications (like Wegovy and Zepbound)
- Coverage is available for beneficiaries with a BMI of 30+ (or 27+ with a weight-related condition like high blood pressure, sleep apnea, or heart disease)
- Plans may require prior authorization and documentation from your doctor
- Not all Part D plans are required to cover every weight loss drug - formularies vary
How Much Will It Cost on Medicare Part D?
Even with Part D coverage, GLP-1 drugs aren't cheap. Here's what to expect in 2026:
- Retail price without insurance: $900 to $1,350 per month
- With Part D coverage: Your cost depends on which formulary tier the drug falls on - typically Tier 4 (non-preferred specialty) or Tier 5 (specialty)
- Typical out-of-pocket with Part D: $50 to $300 per month depending on your plan and the coverage stage you're in
- Annual cap protection: Thanks to the $2,100 out-of-pocket cap on Part D in 2026, your total prescription costs are limited no matter how expensive the drug
Real-world example: Linda, 68, in Omaha has a BMI of 34 and high blood pressure. Her doctor prescribes Wegovy. Her Part D plan covers it on Tier 4 with a $150/month copay. After she hits the $2,100 annual out-of-pocket cap (around month 8), she pays $0 for the rest of the year.
Is Ozempic Covered Differently Than Wegovy?
Yes - and this matters. Ozempic is FDA-approved for type 2 diabetes, not weight loss. Wegovy uses the same active ingredient (semaglutide) but is approved for chronic weight management.
- If you have type 2 diabetes, your Part D plan likely covers Ozempic (and has for years)
- If you're using it purely for weight loss, you'll need Wegovy or Zepbound - the obesity-indicated versions - to qualify under the new Part D coverage
- Some doctors prescribe Ozempic "off-label" for weight loss, but Medicare generally won't cover off-label use for this purpose
How to Check if Your Plan Covers Weight Loss Drugs
- Check your plan's formulary. Every Part D plan publishes a drug list. Search for the specific medication (Wegovy, Zepbound, etc.) to see if it's listed and which tier it's on.
- Ask about prior authorization requirements. Most plans require your doctor to submit documentation proving medical necessity - BMI, comorbidities, and sometimes evidence that you've tried lifestyle changes first.
- Compare plans during Annual Enrollment. If your current plan doesn't cover your medication (or places it on an expensive tier), you can switch to a plan that does during Annual Enrollment Period (October 15, December 7).
- Work with a licensed agent. An independent agent can run your specific medications through a plan comparison tool and find the Part D plan with the lowest total annual cost - not just the lowest premium.
What About Medicare Advantage Plans?
Most Medicare Advantage plans include Part D drug coverage. The same 2026 rule change applies - MA plans with drug coverage can now include anti-obesity medications on their formularies.
However, Medicare Advantage plans may have stricter prior authorization requirements and step therapy protocols (requiring you to try cheaper alternatives first). If you're on a Medicare Supplement plan, you'll have a standalone Part D plan instead, which may offer more flexibility in drug choice.
Common Mistakes to Avoid
- Assuming all Part D plans cover the same drugs. Formularies vary dramatically. One plan may cover Wegovy on Tier 3; another may not cover it at all.
- Not reviewing your plan annually. Drug coverage changes every year. The plan that was cheapest last year may have dropped your medication or moved it to a higher tier.
- Ignoring the $2,100 cap. Even if your monthly copay seems high, remember that your total out-of-pocket for all prescriptions is capped at $2,100 in 2026. Factor this into your annual cost calculation.
- Using manufacturer coupons with Medicare. Unlike commercial insurance, Medicare beneficiaries generally cannot use manufacturer copay cards for GLP-1 drugs. Novo Nordisk and Lilly savings programs typically exclude Medicare patients.
Will Medicare Cover Future Weight Loss Drugs?
The pharmaceutical pipeline is full of next-generation obesity treatments - oral GLP-1 pills, combination drugs, and longer-acting injectables. As these gain FDA approval and CMS reviews their inclusion, expect Part D formularies to expand. The trend is clearly toward broader coverage as obesity is increasingly recognized as a chronic disease.
Bottom Line
Medicare's coverage of weight loss drugs in 2026 is a game-changer for millions of beneficiaries. But coverage isn't automatic - you need the right Part D plan, the right diagnosis documentation, and an understanding of how your costs will work through the year.
If you're considering a GLP-1 medication and want to find the Part D plan that covers it at the lowest cost, schedule a free consultation. I'll run your medications through every available plan and show you exactly what you'll pay.